CASI Pharmaceuticals, Inc.
CASIF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001962738
No open-market purchases or sales by CASI Pharmaceuticals, Inc. insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $17 in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding CASI Pharmaceuticals, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 18 | 20 | +2 |
| Shares | 275.9K | 252.0K | −23.9K (−8.7%) |
| Value | $1.98M | $909.6K | −$1.07M (−54.1%) |
New holders (6)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Howland Capital Management LLC | 40,429 | $145.9K | 0.01% |
| Catalyst Funds Management Pty Ltd | 1,810 | $6.53K | 0.00% |
| FMR LLC | 500 | $1.80K | 0.00% |
| TD Waterhouse Canada Inc. | 300 | $1.03K | 0.00% |
| IFP Advisors, Inc | 40 | $144 | 0.00% |
| Mendota Financial Group, LLC | 20 | $73 | 0.00% |
Sold out (4)
Institutions that held CASI Pharmaceuticals, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Franklin Resources Inc | 19,743 | $143.5K |
| Citadel Advisors LLC | 12,916 | $93.9K |
| Jane Street Group, LLC | 12,538 | $89.8K |
| UBS Group AG | 1,222 | $8.75K |